Christopher Josep Cummings

US Patent:

20010027182, Oct 4, 2001

Filed:

May 28, 1999

Appl. No.:

09/321916

Inventors:

HUDA Y. ZOGHBI - HOUSTON TX, US
HARRY T. ORR - MINNEAPOLIS MN, US
DONALD B. DEFRANCO - PITTSBURGH PA, US
MICHAEL A. MANCINI - HOUSTON TX, US
DAVID STENOIEN - HOUSTON TX, US
CHRISTOPHER J. CUMMINGS - HOUSTON TX, US

International Classification:

A61K048/00
A01K067/00

US Classification:

514/044000, 514/002000, 800/013000

Abstract:

The present invention provides a novel method for treating neurodegenerative disease in mammals. This method involves the introduction of a therapeutic effective amount of a chaperone, a chaperone-like-compound or a compound which increases proteasome activity into the neurological system of the mammal. There is also a novel method for screening for compounds having chaperone-like activity or having activity to increase proteasome activity. The screening works in either cultured cells or animal models.

US Patent:

20010032339, Oct 18, 2001

Filed:

Jun 19, 2001

Appl. No.:

09/884384

Inventors:

Huda Zoghbi - Houston TX, US
Harry Orr - Minneapolis MN, US
Christopher Cummings - San Francisco CA, US

International Classification:

A01K067/00
A01K067/027

US Classification:

800/013000, 800/018000

Abstract:

The present invention provides a novel method for treating neurodegenerative disease in mammals. This method involves the introduction of a therapeutic effective amount of a chaperone, a chaperone-like-compound or a compound which increases proteasome activity into the neurological system of the mammal. There is also a novel method for screening for compounds having chaperone-like activity or having activity to increase proteasome activity. The screening works in either cultured cells or animal models.

US Patent:

20040045046, Mar 4, 2004

Filed:

Jun 11, 2003

Appl. No.:

10/459188

Inventors:

Huda Zoghbi - Houston TX, US
Kei Watase - Houston TX, US
Christopher Cummings - Brookline MA, US

International Classification:

A01K067/027

US Classification:

800/018000

Abstract:

The present invention utilizes a “knock-in” approach to provide a transgenic mammal containing integrated into its genome a repeating nucleotide sequence encoding a polyglutamine comprising at least about 154, preferably at least about 160, 200, 300, 400, 500, and up to 600 or more contiguous glutamine residues. The transgenic mammals normally display observable phenotypic changes. As such, they may serve as a model for disease processes in humans for such diseases as spinobulbar muscular atrophy (SBMA), Huntington's disease (HD), dentatorubral pallidoluysian atrophy (DRPLA), and the spinocerebellar ataxias types 1, 2, 3, 6, 7, and 17. As a result of displaying pathology indicative of a human disease, the efficacy of an agent for treating human disease may be tested in the transgenic mammals.

US Patent:

20220342392, Oct 27, 2022

Filed:

Apr 20, 2022

Appl. No.:

17/724960

Inventors:

- The Woodlands TX, US
Christopher Brendan Cummings - Spring TX, US

International Classification:

G05B 19/4155

Abstract:

Methods, devices, and platforms related to welds. More particularly a device includes a processor that when in operation receives a first signal indicative of completion of action undertaken with respect to a weld. The processor of the device when in operation generates a data log corresponding to receipt of the first signal for addition to a set of one or more previous data logs that correspond to the weld.